Quanta Therapeutics
Quanta Therapeutics develops oral multi-KRAS inhibitors biased to G12D (QTX3034) and G12V (QTX3544), with responses in pancreatic, colorectal, and endometrial cancer.
Phase 1 data (October 2025) showed confirmed responses for QTX3034 alone and with cetuximab in CRC, PDAC, and endometrial cancer. March 2026 preclinical data showed both compounds retain activity against resistance mechanisms acquired on the pan-RAS(ON) inhibitor daraxonrasib.
Pages like this
not linked directly; found by shared links- CompanyFrontier Medicines
Shares Covalent chemistry for the RAS mutations that still have no drug, KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.
- ProductElironrasib
Shares KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS, The undruggable drivers.
- ProductZoldonrasib
Shares Daraxonrasib, KRAS & RAS inhibitors, RAS / RAF / MEK / ERK (MAPK), KRAS.
- TrialRASolute 302
Shares Daraxonrasib, KRAS & RAS inhibitors, KRAS, The undruggable drivers.
- CompanyRevolution Medicines
Shares Covalent chemistry for the RAS mutations that still have no drug, Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers.
- PairingG12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
Shares Daraxonrasib, RAS / RAF / MEK / ERK (MAPK), KRAS, Pancreatic ductal adenocarcinoma.